ENTA

6.28

7.17% 0.42

Dopo l'orario di chiusura: 6.28

Enanta Pharmaceuticals Inc (ENTA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.86

Aprire:

$5.84

Volume 24 ore:

635.58K

Relative Volume:

2.46

Capitalizzazione di mercato:

$133.10M

Reddito:

$73.62M

Utile/perdita netta:

$-138.24M

Rapporto P/E:

-0.9949

EPS:

-6.3125

Flusso di cassa netto:

$-99.19M

1 W Prestazione:

+4.15%

1M Prestazione:

-30.84%

6M Prestazione:

-45.06%

1 anno Prestazione:

-26.29%

Intervallo 1D:

$5.72

$6.31

Intervallo di 1 settimana:

$5.70

$6.56

Portata 52W:

$5.70

$17.80

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Nome

Enanta Pharmaceuticals Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

617 607 0800

Indirizzo

500 ARSENAL STREET, WATERTOWN, MA

Dipendente

131

Cinguettio

@EnantaPharma

Prossima data di guadagno

2024-11-25

Ultimi documenti SEC

ENTA's Discussions on Twitter

Confronta ENTA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ENTA Enanta Pharmaceuticals Inc	6.28	133.10M	73.62M	-138.24M	-99.19M	-6.56
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-09	Downgrade	JP Morgan	Neutral → Underweight
2023-08-08	Downgrade	Jefferies	Buy → Hold
2022-12-09	Iniziato	H.C. Wainwright	Buy
2022-07-06	Aggiornamento	Evercore ISI	In-line → Outperform
2022-06-01	Aggiornamento	Evercore ISI	Underperform → In-line
2021-10-07	Iniziato	Jefferies	Buy
2021-09-09	Iniziato	SVB Leerink	Mkt Perform
2021-01-29	Aggiornamento	JP Morgan	Underweight → Neutral
2020-11-24	Iniziato	Evercore ISI	Underperform
2020-08-28	Ripresa	ROTH Capital	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-27	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-11-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Downgrade	JP Morgan	Neutral → Underweight
2019-05-24	Iniziato	Wolfe Research	Outperform
2019-04-23	Aggiornamento	Berenberg	Hold → Buy
2018-12-13	Iniziato	Berenberg	Hold
2018-06-06	Iniziato	ROTH Capital	Buy
2018-02-08	Downgrade	JP Morgan	Overweight → Neutral
2018-01-02	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-07-11	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	Barclays	Underweight
2015-10-23	Downgrade	Barclays	Equal Weight → Underweight
2015-10-23	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform

Mostra tutto

Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie

Dec 19, 2024

Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 19, 2024

Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Dec 15, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com

Dec 15, 2024

Dec 14, 2024

(ENTA) Technical Data - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada

Dec 13, 2024

FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World

Dec 13, 2024

Dec 12, 2024

Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat

Dec 12, 2024

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com

Dec 11, 2024

Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 11, 2024

Dec 10, 2024

Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

Enanta logs phase II RSV win with zelicapavir - BioWorld Online

Dec 09, 2024

Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch

Dec 09, 2024

LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire

Dec 09, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace

Dec 09, 2024

Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan

Dec 09, 2024

Dec 06, 2024

Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan

Dec 06, 2024

Dec 05, 2024

Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 04, 2024

Dec 01, 2024

Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 01, 2024

Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat

Dec 01, 2024

Nov 30, 2024

Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com

Nov 30, 2024

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World

Nov 30, 2024

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St

Nov 30, 2024

Nov 29, 2024

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance

Nov 29, 2024

Nov 28, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com

Nov 28, 2024

ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World

Nov 28, 2024

Nov 27, 2024